NASDAQ:PEPG PepGen Q3 2026 Earnings Results & Report $4.79 +2.40 (+100.29%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. PepGen missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.28 versus the -$0.27 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET PepGen EPS ResultsActual EPS-$0.28Consensus EPS -$0.27Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersPepGen Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) PepGen Q3 2026 Earnings FAQ Did PepGen beat earnings estimates for Q3 2026? PepGen (NASDAQ:PEPG) reported earnings of -$0.28 per share for Q3 2026, missing the consensus estimate of -$0.27. The report was announced on Tuesday, November 10, 2026. PepGen Earnings HeadlinesPepGen Stock Doubles in One Session - Here's Why30 minutes ago | benzinga.comPepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional MeasuresNovember 10 at 8:29 AM | finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsNovember 10 at 8:29 AM | finance.yahoo.comPepGen surges on new mid-stage trial data for muscle disorder therapyNovember 10 at 8:29 AM | msn.comPepGen (PEPG) Expected to Post Quarterly Earnings on WednesdayNovember 10 at 3:43 AM | americanbankingnews.comSee More PepGen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email. Email Address About PepGenPepGen (NASDAQ:PEPG) Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing. PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue. The company’s research and development efforts have focused primarily on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Its lead programs include PGN-EDO51, an exon-skipping therapy being developed for a subset of patients with DMD who may benefit from exon 51 skipping, and PGN-EDODM1, an investigational treatment designed to address the underlying RNA-processing defects associated with DM1. PepGen is based in the United States and is advancing these programs through clinical development. James McNally serves as the company’s president and chief executive officer.View PepGen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
